Comparing Cytek Biosciences (NASDAQ:CTKB) & Standard BioTools (NASDAQ:LAB)

Cytek Biosciences (NASDAQ:CTKB – Get Rating) and Standard BioTools (NASDAQ:LAB – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of current recommendations for Cytek Biosciences and Standard BioTools, as provided by MarketBeat.

Get Cytek Biosciences alerts:

Cytek Biosciences presently has a consensus target price of $14.33, indicating a potential upside of 49.77%. Given Cytek Biosciences’ higher probable upside, analysts plainly believe Cytek Biosciences is more favorable than Standard BioTools.

Volatility & Risk

Cytek Biosciences has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cytek Biosciences and Standard BioTools’ revenue, earnings per share (EPS) and valuation.

Cytek Biosciences has higher revenue and earnings than Standard BioTools. Standard BioTools is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

49.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 63.2% of Standard BioTools shares are held by institutional investors. 15.9% of Cytek Biosciences shares are held by company insiders. Comparatively, 51.6% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Cytek Biosciences and Standard BioTools’ net margins, return on equity and return on assets.

Summary

Cytek Biosciences beats Standard BioTools on 10 of the 13 factors compared between the two stocks.

About Cytek Biosciences

(Get Rating)

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.

About Standard BioTools

(Get Rating)

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.